Why This U.S.-Based Cannabis Company Should Be on Your Radar

Cresco Labs ORD (CNSX:CL) recently made the biggest acquisition in the history of the U.S. cannabis company. Is it a buy?

It is hard to keep track of the evolving cannabis market. While investors are familiar with most large-cap pot companies (and there aren’t that many), there are many more marijuana firms that are worth serious consideration. Indeed, many smaller cannabis companies are arguably better bargains, all things considered. Let’s turn our attention to Cresco Labs (CNSX:CL), a Chicago-based pot firm you will want to know about.

Making the best of the U.S. market

The U.S. cannabis market is the largest in the world, but since marijuana is still illegal at the federal level, operating in this market is a challenge. However, there are ways for cannabis companies to operate legally within the U.S. Cresco Labs has managed to pull this off as well as almost any of its peers. The Chicago-based company is currently one of the largest of its kind operating in the U.S.

Could Cresco benefit from the growing U.S. market? The company looks well positioned to do so. First, Cresco — whose main focus is on the medical cannabis market — is currently capable of producing close to 150,000 pounds of cannabis per year. With various ongoing expansion projects, though, Cresco is projected to improve its production capacity to over 500,000 pounds by the end of this year (or about 226,797 kilograms).

Cresco’s production capacity (when it reaches its peak) will be very competitive in the industry. Only about a handful of companies would exceed it. Further, the company is making good use of its product. Cresco currently operates 21 dispensaries (and possesses 51 retail dispensary licences). Cresco prides itself on its differentiated products. The company’s branded products command premiums at the point of sale — an important factor that could help Cresco earn higher margins than pot firms that focus mostly on dried cannabis products.

Cresco is getting larger

There at least is one more reason to be giddy about Cresco’s prospects, and it’s a big one.  The company recently announced it was acquiring Origin House, an Ottawa-based cannabis company that happens to be the leader in the booming California pot market. With its nearly 40 million inhabitants, the Golden State is a larger market than all of Canada. Origin House distributes more cannabis product than any of its competitors in the state.

As Cresco already boasts strong operations elsewhere in the U.S., the acquisition of origin House should make the Chicago-based firm an excellent contender to become one of the leading marijuana companies in North America. Once the deal goes through (pending approval from shareholders and the vote should take place in June), it will be the largest acquisition in the history of the U.S. cannabis market. Thus, if Cresco Labs was unknown before, the company will likely become far more popular among investors and analysts.

The bottom line

While Cresco doesn’t get as many mentions as some of its competitors, astute investors looking to benefit from the growing cannabis market should keep the company in their line of sight. With strong and growing operations in the largest market in the world, growing production capacity, and the coming acquisition of Origin House, Cresco’s market position is very competitive. Cresco’s focus on high-margin products could also pay dividends in the long run.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny has no position in any of the companies mentioned. 

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »